Literature DB >> 1932642

Pathophysiology and treatment of posttransplant hypertension.

R G Luke1.   

Abstract

Post-renal transplant hypertension remains a common problem. The most frequent causes now are chronic rejection and cyclosporine-induced hypertension. Before the development of cyclosporine, renin-dependent hypertension was the dominant pathophysiological mechanism but now, with the widespread use of cyclosporine, a salt-dependent mechanism is the major one. In severe "inappropriate" hypertension, potentially surgically remediable causes such as renal artery stenosis of the allograft artery or renin release from the native kidneys should be considered. Cyclosporine causes hypertension in normal subjects and in all solid organ transplants. The most likely mechanism is renal vasoconstriction with subtle retention of sodium chloride together with systemic vasoconstriction. The vasoconstriction, as yet, is not associated with any specific vasoconstricting agent nor does there appear to be a specific antagonist. Indeed, increased sensitivity to many different vasoconstrictors has been demonstrated. The major site of vasoconstriction appears to be in the afferent arteriole, and optimum antihypertensive therapy is probably provided by calcium channel blockers if the hypertension is due to cyclosporine. Because post-renal transplant hypertension is often multifactorial in origin, however, it is not surprising that the use of combined antihypertensives is often necessary.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1932642     DOI: 10.1681/ASN.V22s37

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  14 in total

1.  The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats.

Authors:  Michael M Yeboah; Md Abdul Hye Khan; Marla A Chesnik; Amit Sharma; Mahesh P Paudyal; John R Falck; John D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2016-06-29

2.  Use of ambulatory blood pressure monitoring in kidney transplant recipients.

Authors:  Adrian M Whelan; Elaine Ku
Journal:  Nephrol Dial Transplant       Date:  2019-09-01       Impact factor: 5.992

Review 3.  Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 4.  The clinical and economic potential of cyclosporin drug interactions.

Authors:  J E Martin; A J Daoud; T J Schroeder; M R First
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 5.  Pharmacologic treatment of chronic pediatric hypertension.

Authors:  Renee F Robinson; Milap C Nahata; Donald L Batisky; John D Mahan
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 6.  Hypertensive crisis in children.

Authors:  Jayanthi Chandar; Gastón Zilleruelo
Journal:  Pediatr Nephrol       Date:  2011-07-20       Impact factor: 3.714

Review 7.  Assessment and management of hypertension in transplant patients.

Authors:  Matthew R Weir; Ellen D Burgess; James E Cooper; Andrew Z Fenves; David Goldsmith; Dianne McKay; Anita Mehrotra; Mark M Mitsnefes; Domenic A Sica; Sandra J Taler
Journal:  J Am Soc Nephrol       Date:  2015-02-04       Impact factor: 10.121

8.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

Review 9.  Treatment of hypertension in children.

Authors:  A R Sinaiko
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

Review 10.  Pathomechanisms and the diagnosis of arterial hypertension in pediatric renal allograft recipients.

Authors:  R Büscher; U Vester; A-M Wingen; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2004-11       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.